- Gastroenterology Advisor

Gastric Malignancies


Latest Articles

FDA_drug approval

Ayvakit Approval for GI Stromal Tumor With PDGFRAM Mutation

The FDA has approved Ayvakit (avapritinib; Blueprint Medicines Corporation), a tyrosine kinase inhibitor, for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.

T2DM Increases Gastric Cancer Risk After H. Pylori Eradication

Type 2 diabetes was linked to an increased risk for gastric cancer (adjusted hazard ratio, 1.73). Stratified statistical analysis demonstrated a significantly higher risk for gastric cardia cancer (adjusted hazard ratio, 3.40) and a significantly increased risk in those with suboptimal glycemic control (adjusted hazard ratio, 1.68).